Promising FNAIT prevention study halted early after just one participant
NCT ID NCT06435845
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called RLYB212 in pregnant women at high risk for a condition where the mother's immune system attacks the baby's platelets, causing dangerous bleeding. The goal was to see if the drug was safe and how it moved through the body. Only one woman enrolled before the study was stopped early, so we have very limited information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Leids Universitair Medisch Centrum
Leiden, South Holland, 2333, Netherlands
-
Oslo University Hospital- Ullevål
Oslo, Oslo, 0450, Norway
-
Södersjukhuset
Stockholm, Stockholm County, 118 83, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.